Literature DB >> 8200218

Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone.

J D Wang1, W L Shi, G Q Zhang, X M Bai.   

Abstract

The present study was designed to examine the effect RU 486 administration on steroid hormone levels in serum and decidua. Sixty women at 6-7 weeks gestation were divided into three groups. The first group took a placebo 24 hours before interruption of pregnancy. The other two groups took 200 mg mifepristone 12 and 24 hours before the surgical procedure, respectively. The concentrations of steroids and mifepristone were measured by radioimmunoassay or high performance liquid chromatography. Mifepristone treatment increased the levels of estradiol, cortisol and testosterone in serum and decidual cytosol (p < 0.05 or p < 0.01). A minor elevation in progesterone level was observed but was not statistically significant. The tissue levels of progesterone, estradiol and testosterone were much higher than the serum levels, whereas RU 486 concentration in the tissue was only one-third of the serum level. In addition, the RU 486 level in decidual cytosol was of the same order as that of progesterone. This competitive concentration was not achieved in chorionic villi in our previous observation, explaining why mifepristone exerts its predominant effect on decidua rather than villi. It is concluded that RU 486 reached an effective inhibitory concentration in decidua and had significant effects on the endocrine milieu.

Entities:  

Keywords:  Androgens; Asia; Biology; China; Clinical Research; Clinical Trials; Cytologic Effects; Developing Countries; Eastern Asia; Endocrine System; Estradiol; Estrogens; Examinations And Diagnoses; Hormone Antagonists; Hormones; Laboratory Examinations And Diagnoses; Physiology; Progestational Hormones; Progesterone; Research Report; Ru-486--administraction and dosage; Testosterone

Mesh:

Substances:

Year:  1994        PMID: 8200218     DOI: 10.1016/0010-7824(94)90042-6

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

1.  Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Authors:  Maxwell N Skor; Erin L Wonder; Masha Kocherginsky; Anju Goyal; Ben A Hall; Yi Cai; Suzanne D Conzen
Journal:  Clin Cancer Res       Date:  2013-09-09       Impact factor: 12.531

2.  The OECD validation program of the H295R steroidogenesis assay: Phase 3. Final inter-laboratory validation study.

Authors:  Markus Hecker; Henner Hollert; Ralph Cooper; Anne Marie Vinggaard; Yumi Akahori; Margaret Murphy; Christine Nellemann; Eric Higley; John Newsted; John Laskey; Angela Buckalew; Stefanie Grund; Sibylle Maletz; John Giesy; Gary Timm
Journal:  Environ Sci Pollut Res Int       Date:  2010-10-03       Impact factor: 4.223

3.  Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.

Authors:  Erica M Stringer-Reasor; Gabrielle M Baker; Maxwell N Skor; Masha Kocherginsky; Ernst Lengyel; Gini F Fleming; Suzanne D Conzen
Journal:  Gynecol Oncol       Date:  2015-06-24       Impact factor: 5.482

4.  Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice.

Authors:  Wei Yao; Weiwei Dai; Mohammad Shahnazari; Aaron Pham; Zhiqiang Chen; Haiyan Chen; Min Guan; Nancy E Lane
Journal:  PLoS One       Date:  2010-07-01       Impact factor: 3.240

5.  Quantitative analysis of RU38486 (mifepristone) by HPLC triple quadrupole mass spectrometry.

Authors:  Natalie Z M Homer; Rebecca M Reynolds; Cecilia Mattsson; Matthew A Bailey; Brian R Walker; Ruth Andrew
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-12-27       Impact factor: 3.205

6.  Hypogonadism induced by surgical stress and brain trauma is reversed by human chorionic gonadotropin in male rats: A potential therapy for surgical and TBI-induced hypogonadism?

Authors:  Rastafa I Geddes; Amita Kapoor; Kentaro Hayashi; Ryan Rauh; Marlyse Wehber; Quinn Bongers; Alex D Jansen; Icelle M Anderson; Gabrielle Farquhar; Sivan Vadakkadath-Meethal; Toni E Ziegler; Craig S Atwood
Journal:  Endocrinol Diabetes Metab       Date:  2021-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.